Diabetes & Metabolic Syndrome-Clinical Research & Reviews最新文献_第10页

Effect of stevia on blood glucose and HbA1C: A meta-analysis 甜菊糖对血糖和 HbA1C 的影响：一项荟萃分析。

IF 4.3

Diabetes & Metabolic Syndrome-Clinical Research & Reviews Pub Date : 2024-07-01 DOI: 10.1016/j.dsx.2024.103092

Marzieh Zare , Mobina Zeinalabedini , Soraiya Ebrahimpour-Koujan , Nick Bellissimo , Leila Azadbakht

{"title":"Effect of stevia on blood glucose and HbA1C: A meta-analysis","authors":"Marzieh Zare , Mobina Zeinalabedini , Soraiya Ebrahimpour-Koujan , Nick Bellissimo , Leila Azadbakht","doi":"10.1016/j.dsx.2024.103092","DOIUrl":"10.1016/j.dsx.2024.103092","url":null,"abstract":"<div><h3>Background</h3><p>The study investigates substituting non-nutritive sweeteners (NNS) for sugar to address health concerns related to excess sugar intake. It specifically examines how stevia affects insulin and blood glucose levels. The systematic review and meta-analysis aim to evaluate stevia's impact on glycemic indices.</p></div><div><h3>Methods</h3><p>We conducted a systematic review and meta-analysis following PRISMA guidelines, including 26 studies with 1439 participants. The PROSPERO registration number for this research is CRD42023414411. We systematically searched PubMed (MEDLINE), Scopus, Web of Science, and Google Scholar. Additionally, we thoroughly reviewed the reference lists of the articles we extracted and relevant reviews. Two evaluators independently carried out screening, quality assessment, and data extraction. The GRADE (grading of recommendations, assessment, development, and evaluation) approach was utilized to evaluate the certainty of the evidence.</p></div><div><h3>Results</h3><p>Stevia consumption was associated with significantly reducing blood glucose levels (WMD: −3.84; 95 % CI: −7.15, −0.53; P = 0.02, low certainty), especially in individuals with higher BMI, diabetes, and hypertension. Dose-response analysis revealed a decrease in blood glucose for ≥3342 mg/day of stevia consumption. Stevia consumption has been shown to reduce blood glucose levels within 1–4 months, as evidenced by dose-response analysis (less than 120 days) and subgroup analysis (more than four weeks). However, stevia did not significantly affect insulin concentration or HbA1C levels (very low and low certainty, respectively).</p></div><div><h3>Conclusions</h3><p>Low certainty evidence showed that stevia improved blood glucose control, especially when consumed for less than 120 days. However, more randomized trials with higher stevia dosages are required.</p></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"18 7","pages":"Article 103092"},"PeriodicalIF":4.3,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141890500","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Enrollment of Black, Indigenous and People of Color (BIPOC) and female participants in the US diabetes trials spanning 2000 to 2020: A chronological survey 2000 年至 2020 年美国糖尿病试验中黑人、原住民、有色人种 (BIPOC) 和女性参与者的注册情况：按时间顺序进行的调查

IF 4.3

Diabetes & Metabolic Syndrome-Clinical Research & Reviews Pub Date : 2024-07-01 DOI: 10.1016/j.dsx.2024.103074

Jingyi Zhang , Miaoguan Peng , Jianfeng Li , Likang Li , Xuerui Bai , Lehana Thabane , Gregory Yh Lip , Harriette GC. Van Spall , Guowei Li

{"title":"Enrollment of Black, Indigenous and People of Color (BIPOC) and female participants in the US diabetes trials spanning 2000 to 2020: A chronological survey","authors":"Jingyi Zhang , Miaoguan Peng , Jianfeng Li , Likang Li , Xuerui Bai , Lehana Thabane , Gregory Yh Lip , Harriette GC. Van Spall , Guowei Li","doi":"10.1016/j.dsx.2024.103074","DOIUrl":"10.1016/j.dsx.2024.103074","url":null,"abstract":"<div><h3>Aims</h3><p>Little is known about the enrollment practice of both Black, Indigenous and People of Color (BIPOC) and females in the US diabetes trials. We aimed to perform a chronological survey to evaluate the enrollment of BIPOC and female participants in the US diabetes randomized controlled trials (RCTs) over the past two decades.</p></div><div><h3>Methods</h3><p>We searched databases to systematically include the US diabetes RCTs from 2000 January 1st to 2020 December 31st. Primary outcome was the adequate enrollment of both BIPOC and females, defined by the participation to prevalence ratio (PPR) > 0.8. We tested the temporal trend in adequate enrollment over time and used logistic regression analysis to explore the relationship between adequate enrollment and trial characteristics.</p></div><div><h3>Results</h3><p>A total of 69 US diabetes trials were included for analyses, with a median BIPOC and female enrollment percentage of 29.0 % and 45.4 % respectively. There were 22 (31.9 %) trials with adequate enrollment of both BIPOC and females. No significant trend of adequate enrollment percentage of BIPOC and females over time was observed (<em>P</em> = 0.16). Of trial types, those with medication interventions were significantly related to decreased odds of adequate enrollment, when compared to trials with non-drug interventions (odds ratio = 0.29, 95 % confidence interval: 0.11–0.84).</p></div><div><h3>Conclusions</h3><p>Less than one third of the US diabetes trials adequately enrolled both BIPOC and females over the past two decades, and no temporal improvement in BIPOC and female participant enrollment was observed. These results highlight the need for more endeavors to mitigate inadequate representation regarding BIPOC and female enrollment in diabetes trials.</p></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"18 7","pages":"Article 103074"},"PeriodicalIF":4.3,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141691856","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Impact of coffee and its bioactive compounds on the risks of type 2 diabetes and its complications: A comprehensive review 咖啡及其生物活性化合物对 2 型糖尿病及其并发症风险的影响：全面综述

IF 4.3

Diabetes & Metabolic Syndrome-Clinical Research & Reviews Pub Date : 2024-07-01 DOI: 10.1016/j.dsx.2024.103075

Almahi I. Mohamed , Ochuko L. Erukainure , Veronica F. Salau , Md Shahidul Islam

{"title":"Impact of coffee and its bioactive compounds on the risks of type 2 diabetes and its complications: A comprehensive review","authors":"Almahi I. Mohamed , Ochuko L. Erukainure , Veronica F. Salau , Md Shahidul Islam","doi":"10.1016/j.dsx.2024.103075","DOIUrl":"10.1016/j.dsx.2024.103075","url":null,"abstract":"<div><h3>Background</h3><p>Coffee beans have a long history of use as traditional medicine by various indigenous people. Recent focus has been given to the health benefits of coffee beans and its bioactive compounds. Research on the bioactivities, applications, and effects of processing methods on coffee beans' phytochemical composition and activities has been conducted extensively. The current review attempts to provide an update on the biological effects of coffee on type 2 diabetes (T2D) and its comorbidities.</p></div><div><h3>Methods</h3><p>Comprehensive literature search was carried out on peer-reviewed published data on biological activities of coffee on <em>in vitro</em>, <em>in vivo</em> and epidemiological research results published from January 2015 to December 2022, using online databases such as PubMed, Google Scholar and ScienceDirect for our searches.</p></div><div><h3>Results</h3><p>The main findings were: firstly, coffee may contribute to the prevention of oxidative stress and T2D-related illnesses such as cardiovascular disease, retinopathy, obesity, and metabolic syndrome; secondly, consuming up to 400 mg/day (1–4 cups per day) of coffee is associated with lower risks of T2D; thirdly, caffeine consumed between 0.5 and 4 h before a meal may inhibit acute metabolic rate; and finally, both caffeinated and decaffeinated coffee are associated with reducing the risks of T2D.</p></div><div><h3>Conclusion</h3><p>Available evidence indicates that long-term consumption of coffee is associated with decreased risk of T2D and its complications as well as decreased body weight. This has been attributed to the consumption of coffee with the abundance of bioactive chemicals.</p></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"18 7","pages":"Article 103075"},"PeriodicalIF":4.3,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S187140212400136X/pdfft?md5=eb0e2a8cd5e009c11ab31f87f64a5067&pid=1-s2.0-S187140212400136X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141694595","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Comprehensive investigation of insulin-induced amyloidosis lesions in patients with diabetes at clinical and histological levels: A systematic review 从临床和组织学层面全面研究糖尿病患者的胰岛素诱导淀粉样变性病变：系统综述

IF 4.3

Diabetes & Metabolic Syndrome-Clinical Research & Reviews Pub Date : 2024-07-01 DOI: 10.1016/j.dsx.2024.103083

Leyla Karkhaneh , Shaghayegh Hosseinkhani , Hossein Azami , Yalda Karamlou , Ali Sheidaei , Ensieh Nasli-Esfahani , Farideh Razi , Azadeh Ebrahim-Habibi

{"title":"Comprehensive investigation of insulin-induced amyloidosis lesions in patients with diabetes at clinical and histological levels: A systematic review","authors":"Leyla Karkhaneh , Shaghayegh Hosseinkhani , Hossein Azami , Yalda Karamlou , Ali Sheidaei , Ensieh Nasli-Esfahani , Farideh Razi , Azadeh Ebrahim-Habibi","doi":"10.1016/j.dsx.2024.103083","DOIUrl":"10.1016/j.dsx.2024.103083","url":null,"abstract":"<div><h3>Introduction</h3><p>Insulin-derived amyloidosis (AIns), a skin complication in patients with diabetes, causes impaired insulin absorption. This systematic review aims to get a better understanding of this overlooked condition.</p></div><div><h3>Methods</h3><p>Comprehensive literature searches were performed in Scopus, PubMed, EMBASE, and Web of Science databases until June 17, 2023. From 19,343 publications, duplicate and irrelevant records were eliminated by title, and the full texts of the remaining studies were examined for validity. Clinical, pathological, and therapeutic findings were extracted from 44 papers.</p></div><div><h3>Results</h3><p>Forty-four articles were studied that covered 127 insulin-treated patients with diabetes. From the 62 patients with reported age and sex, males had a mean age of 58 years, and females 68.5 years. While AIns were twice as likely to develop in men (66.13 %) as in women (33.87 %), the administered insulin dose was significantly higher in males (p = 0.017). The most common insulin injection site was the abdominal wall (77.63 %). Histological findings showed the presence of amorphous material with the occasional presence of lymphocytes, plasma cells, macrophages, adipocytes, histocytes, and giant cells. The mean HbA1c level was 8.8 % and the need for receiving insulin was increased in AIns. Changing the site of insulin injections and/or surgically removing the nodules were the most common treatments to obtain better insulin uptake and controlled serum glucose levels.</p></div><div><h3>Conclusion</h3><p>This study highlights the importance of AIns, proper rotation of insulin injection site, and post-treatment patient follow-up to recognize and prevent the development of amyloid nodules.</p></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"18 7","pages":"Article 103083"},"PeriodicalIF":4.3,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141846181","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Yoga and prevention of type 2 diabetes - The Indian Prevention of Diabetes Study (IPDS) 瑜伽与 2 型糖尿病的预防--印度预防糖尿病研究（IPDS）

IF 4.3

Diabetes & Metabolic Syndrome-Clinical Research & Reviews Pub Date : 2024-07-01 DOI: 10.1016/j.dsx.2024.103088

Sri V. Madhu , Paturi V. Rao , Hemraj B. Chandalia , Kesavadev Jothydev , Arvind Gupta , for Research Society for the Study of Diabetes in India

{"title":"Yoga and prevention of type 2 diabetes - The Indian Prevention of Diabetes Study (IPDS)","authors":"Sri V. Madhu , Paturi V. Rao , Hemraj B. Chandalia , Kesavadev Jothydev , Arvind Gupta , for Research Society for the Study of Diabetes in India","doi":"10.1016/j.dsx.2024.103088","DOIUrl":"10.1016/j.dsx.2024.103088","url":null,"abstract":"<div><h3>Background</h3><p>Short term studies have reported that yoga could be beneficial in preventing diabetes. We evaluated long term effectiveness of yoga in reducing the risk of type 2 diabetes.</p></div><div><h3>Methods</h3><p>This open labelled randomized controlled trial was conducted across five medical centers. Adults diagnosed with prediabetes following an oral glucose tolerance test were randomly assigned to receive a structured yoga intervention consisting of 40 minutes of specific yoga asanas pranayama in addition to standard lifestyle measures or standard lifestyle measures alone. The primary outcome of incident diabetes was compared in both groups at the end of the 3-year intervention period using intention-to-treat analysis.</p></div><div><h3>Results</h3><p>A total of 974 individuals were randomized (488 to the yoga + lifestyle group-group1 and 486 to the Lifestyle alone group-group2). After 3 years of follow-up, there was a 39.2 % reduction of the relative risk of diabetes with yoga (11.5 % in group1 vs 18.9 % in group 2). Cox proportional hazard model analysis revealed a significantly higher odds ratio of 1.74 (95 % CI 1.25–2.43) of developing diabetes in the lifestyle alone group compared to those who also performed yoga. Adherence to yoga was good with 77 % of individuals performing yoga for more than 75 % of the time.</p></div><div><h3>Conclusions</h3><p>Structured yoga intervention along with standard lifestyle measures significantly reduces risk of type 2 diabetes when compared with those given lifestyle measures alone.</p></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"18 7","pages":"Article 103088"},"PeriodicalIF":4.3,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141851374","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Association between dietary protein intake and mortality among patients with diabetic kidney disease 膳食蛋白质摄入量与糖尿病肾病患者死亡率之间的关系

IF 4.3

Diabetes & Metabolic Syndrome-Clinical Research & Reviews Pub Date : 2024-07-01 DOI: 10.1016/j.dsx.2024.103091

Yichuan Wu , Jiaqi Chen , Yuan Tao , Manlu Xiao , Jingrong Xiong , Aomiao Chen , Xiaoqin Ma , Linna Li , Hongxia Jia , Qian Zhang , Yaoming Xue , Yijie Jia , Zongji Zheng

{"title":"Association between dietary protein intake and mortality among patients with diabetic kidney disease","authors":"Yichuan Wu , Jiaqi Chen , Yuan Tao , Manlu Xiao , Jingrong Xiong , Aomiao Chen , Xiaoqin Ma , Linna Li , Hongxia Jia , Qian Zhang , Yaoming Xue , Yijie Jia , Zongji Zheng","doi":"10.1016/j.dsx.2024.103091","DOIUrl":"10.1016/j.dsx.2024.103091","url":null,"abstract":"<div><h3>Aims</h3><p>This study aimed to investigate the association between dietary protein intake and mortality among patients with diabetic kidney disease.</p></div><div><h3>Methods</h3><p>The research encompassed a total of 2901 participants diagnosed with diabetic kidney disease, drawn from the National Health and Nutrition Examination Survey (NHANES). To determine outcomes related to all-cause and cardiovascular mortality, connections were established with the National Death Index up until December 31, 2019. Estimations of hazard ratios (HRs) and their corresponding 95 % confidence intervals (CIs) were conducted using Cox proportional hazard ratio models.</p></div><div><h3>Results</h3><p>During the 261,239 person-years of follow-up, 1236 deaths were recorded. After multivariate adjustment, the weighted hazard ratio (HR) and 95 % CIs for participants with 1.0–1.2 g/kg of protein intake was 0.65 (0.44, 0.96) for all-cause mortality. A higher proportion of animal protein intake was found to be associated with an increased mortality risk. Stratified analyses showed that higher protein intake benefited older participants.</p></div><div><h3>Conclusions</h3><p>In diabetic kidney disease patients, 1.0–1.2 g/kg of protein was associated with lower mortality and 0.6–1.2 g/kg of protein especially benefitted patients ≥60 years.</p></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"18 7","pages":"Article 103091"},"PeriodicalIF":4.3,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141843991","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Exploring effects of melatonin supplementation on insulin resistance: An updated systematic review of animal and human studies 探索补充褪黑素对胰岛素抵抗的影响：动物和人体研究的最新系统回顾

IF 4.3

Diabetes & Metabolic Syndrome-Clinical Research & Reviews Pub Date : 2024-07-01 DOI: 10.1016/j.dsx.2024.103073

Fakhrosadat Fayazi , Sorayya Kheirouri , Mohammad Alizadeh

{"title":"Exploring effects of melatonin supplementation on insulin resistance: An updated systematic review of animal and human studies","authors":"Fakhrosadat Fayazi , Sorayya Kheirouri , Mohammad Alizadeh","doi":"10.1016/j.dsx.2024.103073","DOIUrl":"10.1016/j.dsx.2024.103073","url":null,"abstract":"<div><h3>Background</h3><p>Insulin resistance (IR), defined as an impaired response to insulin stimulation of target tissues, is a substantial determinant of many metabolic disorders. This study aimed to update the findings of the previous systematic review evidence regarding the effect of melatonin on factors related to IR, including hyperinsulinemia, hyperglycemia, homeostasis model assessment of insulin resistance (HOMA-IR), and quantitative insulin sensitivity check index (QUICKI).</p></div><div><h3>Methods</h3><p>We systematically reviewed the evidence on the impact of melatonin supplementation on IR indices, fasting insulin, and fasting plasma glucose. PubMed, ScienceDirect, SCOPUS, and Google Scholar databases were searched until March 2024.</p></div><div><h3>Results</h3><p>We identified 6114 potentially relevant articles during the search. Eighteen animal studies and 15 randomized clinical trials met the inclusion criteria. The results indicated that melatonin supplementation reduced fasting plasma glucose (FPG, 14 out of 29 studies), fasting insulin (22 out of 28 studies), HOMA-IR (28 out of 33 studies), and increased QUICKI (7 out of 7 studies). According to RCT studies, melatonin treatment at a dosage of 10 mg reduced HOMA-IR levels in individuals with various health conditions.</p></div><div><h3>Conclusion</h3><p>According to most evidence, melatonin supplementation may decrease fasting insulin and HOMA-IR and increase QUICKI but may not affect FPG.</p></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"18 7","pages":"Article 103073"},"PeriodicalIF":4.3,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141852370","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clinical Practice Guidelines for the Management of Type 2 Diabetes in South Asia: A Systematic Review 南亚 2 型糖尿病管理临床实践指南：系统回顾。

IF 4.3

Diabetes & Metabolic Syndrome-Clinical Research & Reviews Pub Date : 2024-07-01 DOI: 10.1016/j.dsx.2024.103094

Alina Pervez , Areesha Ahmer , Omar Mahmud , Russell Seth Martins , Hawra Hussain , Sameen Nasir , Sonia Pirzada , Mohsin Ali Mustafa , Uswah Siddiqi , Maheen Zakaria , Nashia Ali Rizvi , Ainan Arshad , Adil H. Haider , Sarah Nadeem

{"title":"Clinical Practice Guidelines for the Management of Type 2 Diabetes in South Asia: A Systematic Review","authors":"Alina Pervez , Areesha Ahmer , Omar Mahmud , Russell Seth Martins , Hawra Hussain , Sameen Nasir , Sonia Pirzada , Mohsin Ali Mustafa , Uswah Siddiqi , Maheen Zakaria , Nashia Ali Rizvi , Ainan Arshad , Adil H. Haider , Sarah Nadeem","doi":"10.1016/j.dsx.2024.103094","DOIUrl":"10.1016/j.dsx.2024.103094","url":null,"abstract":"<div><h3>Background</h3><p>Clinical practice guidelines (CPGs) are a helpful tool for the evidence-based management of Type 2 Diabetes Mellitus (T2D). The aim of this systematic review was to synthesize and appraise the scope and quality of South Asian T2D CPGs.</p></div><div><h3>Methods</h3><p>This PROPSERO registered (CRD42023425150) systematic review adhered to the 2020 PRISMA guidelines. We searched the PubMed, Embase, Cochrane, and Google Scholar databases for relevant guidelines. Data synthesis was performed using a qualitative approach and methodological quality was assessed using the Appraisal of Guidelines for Research and Evaluation (AGREE) II tool.</p></div><div><h3>Results</h3><p>We identified eleven unique CPGs (three each from Pakistan and Sri Lanka, two from India, and one each from Bangladesh, Nepal, and Bhutan) which were published or updated between 2017 and 2023. The CPGs included recommendations regarding screening, diagnosis, prevention, and management of T2D and its acute and chronic complications, comorbidities, and fasting with T2D. The AGREE II mean domain scores ranged from 37 % to 80 %; three CPGs were ‘recommended for clinical use,’ seven were ‘recommended for use with modifications’ and one was deemed unfit for implementation.</p></div><div><h3>Conclusion</h3><p>The present review summarized and appraised broadly CPGs from South Asia for T2D and can help direct improvements to future iterations.</p></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"18 7","pages":"Article 103094"},"PeriodicalIF":4.3,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141903242","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Asprosin levels in patients with type 2 diabetes mellitus, metabolic syndrome and obesity: A systematic review and meta-analysis 2 型糖尿病、代谢综合征和肥胖症患者体内的阿司匹林水平：系统回顾与荟萃分析。

IF 4.3

Diabetes & Metabolic Syndrome-Clinical Research & Reviews Pub Date : 2024-07-01 DOI: 10.1016/j.dsx.2024.103095

Juan R. Ulloque-Badaracco , Ali Al-kassab-Córdova , Enrique A. Hernandez-Bustamante , Esteban A. Alarcon-Braga , Pamela Robles-Valcarcel , Miguel A. Huayta-Cortez , Juan C. Cabrera Guzmán , Rosa A. Seminario-Amez , Vicente A. Benites-Zapata

{"title":"Asprosin levels in patients with type 2 diabetes mellitus, metabolic syndrome and obesity: A systematic review and meta-analysis","authors":"Juan R. Ulloque-Badaracco , Ali Al-kassab-Córdova , Enrique A. Hernandez-Bustamante , Esteban A. Alarcon-Braga , Pamela Robles-Valcarcel , Miguel A. Huayta-Cortez , Juan C. Cabrera Guzmán , Rosa A. Seminario-Amez , Vicente A. Benites-Zapata","doi":"10.1016/j.dsx.2024.103095","DOIUrl":"10.1016/j.dsx.2024.103095","url":null,"abstract":"<div><h3>Background & aims</h3><p>Asprosin is a promising candidate for novel treatments for metabolic–endocrine disorders. The objective of this systematic review and meta-analysis was to consolidate the existing evidence regarding asprosin levels in patients diagnosed with type 2 diabetes (T2D), metabolic syndrome (MetS), and obesity.</p></div><div><h3>Methods</h3><p>Scopus, Embase, PubMed, Ovid/Medline, and Web of Science were systematically searched without restrictions. We only used the standardized mean differences (SMD) with their 95 % confidence intervals (95 % CI) as the effect measure. A random-effects model (DerSimonian and Laird method) was used for the meta-analysis. Risk of bias was assessed with the Newcastle–Ottawa Scale and Newcastle–Ottawa Scale for Cross-Sectional Studies.</p></div><div><h3>Results</h3><p>Twenty-six studies (n = 3,787) were included in the meta-analysis. Participants with T2D had higher asprosin values than those without T2D (SMD: 1.64; 95 % CI: 1.08–2.21; I<sup>2</sup> = 97 %). Patients with MetS had higher asprosin levels compared to those without MetS (SMD: 0.99; 95 % CI: 0.34–1.64; I<sup>2</sup> = 96 %). Patients with obesity had higher asprosin levels than participants without obesity (SMD: 1.49; 95 % CI: 0.23–2.76; I<sup>2</sup> = 98 %).</p></div><div><h3>Conclusions</h3><p>Asprosin is significantly higher in patients with either T2D, MetS, or obesity, compared with controls.</p></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"18 7","pages":"Article 103095"},"PeriodicalIF":4.3,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141890499","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Genetic association of glycemic traits and antihyperglycemic agent target genes with the risk of lung cancer: A Mendelian randomization study 血糖特征和降糖药靶基因与肺癌风险的遗传关联：孟德尔随机研究

IF 1

Diabetes & Metabolic Syndrome-Clinical Research & Reviews Pub Date : 2024-06-01 DOI: 10.1016/j.dsx.2024.103048

Wen Sun , Xiaoyu Zhang , Ning Li , Yan He , Jianguang Ji , Deqiang Zheng

{"title":"Genetic association of glycemic traits and antihyperglycemic agent target genes with the risk of lung cancer: A Mendelian randomization study","authors":"Wen Sun , Xiaoyu Zhang , Ning Li , Yan He , Jianguang Ji , Deqiang Zheng","doi":"10.1016/j.dsx.2024.103048","DOIUrl":"10.1016/j.dsx.2024.103048","url":null,"abstract":"<div><h3>Aims</h3><p>To evaluate the potential causal effect of glycemic traits on lung cancer and investigate the impact of antihyperglycemic agent-target genes on lung cancer risk.</p></div><div><h3>Methods</h3><p>Genetic variants associated with glycemic traits, antihyperglycemic agent-target genes, and lung cancer were extracted from the Meta-Analyses of Glucose and Insulin-related traits Consortium (MAGIC), expression quantitative trait loci (eQTLs), protein quantitative trait loci (pQTLs), and the International Lung Cancer Consortium (ILCCO), respectively. Mendelian randomization (MR) analyses were performed to examine the associations of glycemic traits and antihyperglycemic agent-target genes with lung cancer. Mediation analysis was conducted to explore whether overweight operated as a mediator between antihyperglycemic agents and lung cancer outcomes.</p></div><div><h3>Results</h3><p>Genetically determined glycated hemoglobin A1c levels were associated with squamous cell lung cancer (OR = 1.78; 95 % CI, 1.08–2.92; <em>p</em> = 0.023). The <em>PRKAB1</em> gene (the target of metformin) was associated with a lower risk of developing lung adenocarcinoma (OR = 0.85; 95 % CI, 0.76–0.96; <em>p</em> = 0.006). Further mediation analyses did not support overweight as a mediator between <em>PRKAB1</em> activation and lung adenocarcinoma.</p></div><div><h3>Conclusion</h3><p>Our analyses suggest an association of genetically determined abnormal glycemic traits with squamous cell lung cancer. The potential association between <em>PRKAB1</em> activation and a reduced risk of developing lung adenocarcinoma appears to be independent of the anti-obesity effects of metformin, suggesting that <em>PRKAB1</em> activation may have a direct protective effect on lung adenocarcinoma development.</p></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"18 6","pages":"Article 103048"},"PeriodicalIF":10.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141281776","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0